Shuhui Chen

288 FuteZhong Road
Waigaoqiao, 200131, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Discovery of a Macrocyclic Influenza Cap-Dependent Endonuclease Inhibitor.

Discovery of a Macrocyclic Influenza Cap-Dependent Endonuclease Inhibitor.

Journal: Journal of medicinal chemistry

Published: February 01, 2024

The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease.

The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease.

Journal: Hepatology international

Published: November 07, 2023

Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2.

Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2.

Journal: Bioorganic & medicinal chemistry letters

Published: March 20, 2023

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.

Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir.

Journal: Nature microbiology

Published: February 27, 2023

Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.

Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations.

Journal: Bioorganic & medicinal chemistry letters

Published: February 22, 2022

Discovery of 3-Quinazolin-4(3H)-on-3-yl-2,N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors.

Discovery of 3-Quinazolin-4(3H)-on-3-yl-2,N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors.

Journal: ACS medicinal chemistry letters

Published: May 05, 2020

Computation-aided engineering of starch-debranching pullulanase from Bacillus thermoleovorans for enhanced thermostability.

Computation-aided engineering of starch-debranching pullulanase from Bacillus thermoleovorans for enhanced thermostability.

Journal: Applied microbiology and biotechnology

Published: April 16, 2020

Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Therapeutic Effect and Mechanisms of the Novel Monosulfactam 0073.

Journal: Antimicrobial agents and chemotherapy

Published: March 19, 2020

Design, synthesis, and evaluation of a novel macrocyclic anti-EV71 agent.

Design, synthesis, and evaluation of a novel macrocyclic anti-EV71 agent.

Journal: Bioorganic & medicinal chemistry

Published: January 07, 2020

Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Journal: Antimicrobial agents and chemotherapy

Published: September 19, 2019

Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.

Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor.

Journal: ACS medicinal chemistry letters

Published: August 23, 2019

Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

Journal: ACS medicinal chemistry letters

Published: April 24, 2019

Showing 1-12 of 30

Last Updated: 09/26/2026